 |
|
|
|
|
|
February 21, 2006 — In virtually every aspect, 2005 has been another record-breaking, highly productive year for Pharmanex® Global R&D.
Pharmanex® Scientists Create Innovative Products
Pharmanex® created eight new and innovative products in 2005, including g3™ superfruit juice, Xoi Bar™, lifepak® nano, and DuoLean™. In addition, R&D is about to conclude two years of efforts to improve our BioPhotonic Scanner technology, resulting in the new S2 model, which will be officially launched in early March 2006. Finally, R&D aggressively pursued product registrations in preparation for the much anticipated Pharmanex® launch in Russia (2006). Pharmanex® R&D currently maintains a solid new product pipeline with strong innovative projects being prepared for the future.
Pharmanex® Scientists Perform More Studies than Ever
Our clinical and pharmacological laboratories in Beijing and Provo conducted 16 human clinical studies, 190 experimental and pre-clinical studies, 20 toxicology studies and developed 19 new biological efficacy testing methods. Compared to the previous year, the number of studies was significantly greater. For example, we have performed almost twice the number of clinical studies and over ten times more preclinical studies in 2005.
> read more
|
|
|
|
|
|
|
|
|
|
 |
|
Mark R. Bartlett, Ph.D.
Vice President, Pharmanex Global Research and Development
|
|
|
|
Dr. Bartlett obtained degrees in Biochemistry and Organic Chemistry from the Australian National University and a Ph.D. in Immunology and Cell Biology at the John Curtin School of Medical Research in Canberra.
Dr. Bartlett's research experience includes work in the area of cardiovascular disease with an emphasis on the role of free radicals and antioxidants, transplant research, and human autoimmune inflammatory diseases. He has published more than a dozen papers on this work in various scientific journals.
Dr. Bartlett's research then led him to the United States' National Institutes of Health where, as a visiting scientist at the world-renowned National Cancer Institute, he investigated the interaction of T cells with the blood vessel wall.
Dr. Bartlett's interest in the role of nutrition in human health and disease led him to join Interior Design Nutritionals (IDN) in 1996 as a technical specialist and scientific advisor. He has since formulated many supplements and sports food products for the United States, Japan, Taiwan, Korea, Hong Kong, and Australia.
|
|
|
|
